Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:Introduction (00:00)Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39)CME information and select publications